<code id='4230E0E965'></code><style id='4230E0E965'></style>
    • <acronym id='4230E0E965'></acronym>
      <center id='4230E0E965'><center id='4230E0E965'><tfoot id='4230E0E965'></tfoot></center><abbr id='4230E0E965'><dir id='4230E0E965'><tfoot id='4230E0E965'></tfoot><noframes id='4230E0E965'>

    • <optgroup id='4230E0E965'><strike id='4230E0E965'><sup id='4230E0E965'></sup></strike><code id='4230E0E965'></code></optgroup>
        1. <b id='4230E0E965'><label id='4230E0E965'><select id='4230E0E965'><dt id='4230E0E965'><span id='4230E0E965'></span></dt></select></label></b><u id='4230E0E965'></u>
          <i id='4230E0E965'><strike id='4230E0E965'><tt id='4230E0E965'><pre id='4230E0E965'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:5
          People taking notes while sitting around a meeting table
          Adobe

          It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

          In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

          advertisement

          Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal
          Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more

          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

          BiogenCEOChristopherViehbacherSTATTwoyearsafterabigscientificswingnearlypushedBiogentothebrink,CEOCh